All Posts
Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents.
7 Oct, 2021 | 10:14h | UTC
Varied extent of mitral annular disjunction among cases with different phenotypes of mitral valve prolapse.
7 Oct, 2021 | 10:12h | UTC
Commentary on Twitter
Varied Extent of #MAD Among Cases With Different Phenotypes of #Mitral Valve #Prolapse ➡️ 3D #YesCCT ➡️ https://t.co/7q4GqIAZQd @JACCJournals @UCLA @argulian @purviparwani @MinnowWalsh @BakhshiHooman @MrinShettyMD @mividovich #JACCCaseReports @gina_lundberg @chiarabd @EstefaniaOS pic.twitter.com/6gVnaBg3cb
— Julia Grapsa MD, PhD (@JGrapsa) August 18, 2021
Key concepts in clinical epidemiology: Stepped wedge trials.
7 Oct, 2021 | 10:10h | UTCKey concepts in clinical epidemiology: Stepped wedge trials – Journal of Clinical Epidemiology
GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings.
7 Oct, 2021 | 10:11h | UTC
Cohort Study: Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumor types in 61 countries.
6 Oct, 2021 | 10:09h | UTC
Commentary on Twitter (thread – click for more)
What were the unintended consequences of COVID lockdowns on cancer care?@CovidSurg study in @TheLancetOncol:
🔹Lockdowns independently associated with delayed treatment
🔹At median 5.3 months f/u, 1 in 7 pts had not had planned cancer surgery🆓https://t.co/UZe0euq5kg pic.twitter.com/4fPl6UEb9D
— Dmitri Nepogodiev (@dnepo) October 5, 2021
Opinion | Why Are Americans Still—Still!—Wearing Cloth Masks?
6 Oct, 2021 | 10:04h | UTCWhy Are Americans Still—Still!—Wearing Cloth Masks? – The Atlantic
Related:
Evidence shows that, yes, masks prevent COVID-19 – and surgical masks are the way to go.
[Preprint] Largest study of masks yet details their importance in fighting Covid-19.
Commentary on Twitter
Any mask is better than no mask, especially indoors. But for those who are at higher risk of severe disease or around lots of unvaccinated people, consider upgrading to an N95 (or equivalent) mask, which are more protective. https://t.co/vhNPadTP8O
— Dr. Tom Frieden (@DrTomFrieden) October 5, 2021
EMA recommendations on extra doses and boosters of BioNTech/Pfizer and Moderna mRNA vaccines.
6 Oct, 2021 | 10:15h | UTCComirnaty and Spikevax: EMA recommendations on extra doses and boosters – European Medicines Agency
Related: The difference between COVID-19 ‘third doses’ and ‘boosters’ – Emory News Center
Commentary on Twitter
EMA recommended additional doses and boosters for #Comirnaty and #Spikevax. https://t.co/qefPg2kMMO
In this context, see below what the difference between an additional dose and a #boosterdose is. pic.twitter.com/HeyOACbWXm
— EU Medicines Agency (@EMA_News) October 5, 2021
What we know — and don’t know — about Merck’s new Covid-19 pill.
6 Oct, 2021 | 10:07h | UTCWhat we know — and don’t know — about Merck’s new Covid-19 pill – STAT
Related:
Merck’s Covid-19 pill is great news but may not be a game-changer.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
ACOEM Guidance Statement: Prevention of occupational heat-related illnesses.
6 Oct, 2021 | 09:59h | UTC
European Hernia Society guidelines on management of rectus diastasis.
6 Oct, 2021 | 10:02h | UTCEuropean Hernia Society guidelines on management of rectus diastasis – British Journal of Surgery
Commentary on Twitter
🚨🚨🚨🆕@eurohernias Clinical Practice Guideline on the management of rectus #diastasis🚨🚨🚨
Read it for 🆓 here: https://t.co/fxAqcZXrq5#OpenAccess🔓 #SoMe4Surgery #ItsNotJustAHernia #SoMe4Hernia pic.twitter.com/xJS3h0INCd
— BJS (@BJSurgery) October 1, 2021
Cohort study: Adding a new antihypertensive to existing regimens is associated with greater blood pressure reductions than maximizing dose.
6 Oct, 2021 | 09:57h | UTCNews release: When blood pressure needs more control, what’s better: An additional drug or more of the same? – Michigan Medicine
Commentary on Twitter (thread – click for more)
Excited to see our paper in Annals today looking at blood pressure control regiments by adding multiple low dose meds vs. maxing dose then starting new meds. 🧵 https://t.co/3d4L2nZO4v
— Jeremy Sussman (@JeremySussman) October 5, 2021
Clinical Report | Topical nasal decongestant Oxymetazoline: safety considerations for perioperative pediatric use.
6 Oct, 2021 | 10:01h | UTC
RCT: An active strategy for diagnosing pulmonary embolism did not improve outcomes in patients hospitalized for COPD exacerbation.
6 Oct, 2021 | 09:52h | UTCEffect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial – JAMA (free for a limited period)
Commentary on Twitter
Among patients hospitalized for an exacerbation of #COPD, addition of an active diagnostic strategy for pulmonary embolism to usual care compared with usual care alone did not improve a composite set of health outcomes https://t.co/7mOi5lOBD8
— JAMA (@JAMA_current) October 5, 2021
SILENCE Randomized Trial: In patients at the end of life, prophylactic subcutaneous scopolamine butylbromide reduces the occurrence of the death rattle (noisy breathing caused by mucus in the upper respiratory tract).
6 Oct, 2021 | 09:54h | UTCEffect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of LifeThe SILENCE Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Preventing Death Rattle With Prophylactic Subcutaneous Scopolamine Butylbromide – JAMA (free for a limited period)
Author interview: Scopolamine Butylbromide for Preventing End-of-Life Death Rattle – JAMA
Commentary on Twitter
In a randomized clinical trial among patients near the end of life, prophylactic subcutaneous scopolamine butylbromide significantly reduced the occurrence of death rattle https://t.co/e6BDI5yirY pic.twitter.com/hHfhC2iYHh
— JAMA (@JAMA_current) October 5, 2021
Systematic review: Pretomanid for tuberculosis.
6 Oct, 2021 | 08:51h | UTCPretomanid for tuberculosis: a systematic review – Clinical Microbiology and Infection
Related:
Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
WHO announces updated definitions of extensively drug-resistant tuberculosis
Supplement: Triumphs of Vaccination.
6 Oct, 2021 | 08:55h | UTCHomepage: Triumphs of Vaccination – The Journal of Infectious Diseases
Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease
The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease
Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe
Rubella Eradication: Not Yet Accomplished, but Entirely Feasible
Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster
Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication
Influenza Vaccines: Successes and Continuing Challenges
Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination
Overview of the United States’ Immunization Program
The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade
Review: Eosinophilic Esophagitis.
6 Oct, 2021 | 09:51h | UTCEosinophilic Esophagitis: A Review – JAMA (free for a limited period)
Related:
Clinical Guidelines for the Management of Eosinophilic Esophagitis
Eosinophilic Esophagitis: Review and Update
Is salt good for you after all? The evidence says no.
6 Oct, 2021 | 08:52h | UTCIs salt good for you after all? The evidence says no – The Conversation
Related:
Systematic Review: Altered dietary salt intake for people with chronic kidney disease.
New WHO benchmarks help countries reduce salt intake and save lives.
RCT: Reduced-sodium added-potassium salt substitute reduces blood pressure in hypertensive patients
Potassium Enriched Salt Substitution Could Prevent a Large Number of Cardiovascular Deaths
Meta-Analysis: Effect of Reduction in Dietary Sodium on Blood Pressure Levels
Review: Inhibition of platelet aggregation after coronary stenting in patients receiving oral anticoagulation.
6 Oct, 2021 | 08:46h | UTC
Series from the Lancet journals: Hematological malignancies in older people.
6 Oct, 2021 | 08:47h | UTCHomepage: Haematological malignancies in older people – The Lancet Haematology
Commentary: Living longer and better with haematological malignancies: a promise for older adults too? (free registration required)
A comprehensive approach to therapy of haematological malignancies in older patients (free registration required)
Frailty assessment in the care of older people with haematological malignancies
Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care (free registration required)
The diagnosis and management of endocrine side effects of immune checkpoint inhibitors.
6 Oct, 2021 | 08:44h | UTCRelated: Review: Endocrine complications of immunotherapies
Cohort study: Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older is rare, and most cases are not severe.
5 Oct, 2021 | 10:07h | UTCEditorial: COVID-19 Messenger RNA Vaccination and Myocarditis—A Rare and Mostly Mild Adverse Effect
Commentary on Twitter
New report on very rare acute myocarditis after mRNA vaccination in age 18+
5.8 cases/million after 2nd dose, 0.8/million 1st dose, all cases fully resolved with conservative managementhttps://t.co/Mfh5ImiSpW @KPSCALnews @KPSCalResearch @JAMAInternalMed— Eric Topol (@EricTopol) October 4, 2021
Imaging in non-bacterial osteomyelitis in children and adolescents: diagnosis, differential diagnosis and follow-up—an educational review based on a literature survey and own clinical experiences.
6 Oct, 2021 | 08:43h | UTC
Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.
5 Oct, 2021 | 10:09h | UTCCommentary: Expert reaction to study on Pfizer-BioNTech vaccine effectiveness up to 6 months – Science Media Centre
Commentary on Twitter
Study of 3.4 million people @aboutKP @TheLancet
Vaccine efficacy against infections:
– First month post: 88%
– 5 months post: 47%But vaccine efficacy against hospitalization (Figure):
– First month post: 87%
– 5 months post: 88 %https://t.co/1Gse0FKpoI pic.twitter.com/p9wyiaWGeg— Vincent Rajkumar (@VincentRK) October 4, 2021
RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.
5 Oct, 2021 | 10:06h | UTCRelated:
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.